Latest losartan Stories

Although observational studies have suggested that losartan, a drug used primarily for the treatment of hypertension, may be associated with an increased risk of death among patients with heart failure compared with other medications in the same class of drugs (angiotensin II receptor blockers [ARBs]), an analysis that included nearly 6,500 patients found that overall, use of losartan was not associated with increased all-cause death or cardiovascular death compared with use of the ARB...

Chronic obstructive pulmonary disease (COPD) is among the most common causes of death in the US. It is a smoking-related disease for which there are currently no disease-altering therapies. However, hope that one could be developed is now provided by the work of Enid Neptune and colleagues, at Johns Hopkins University, Baltimore, in a mouse model of lung disease caused by exposure to cigarette smoke. Neptune and colleagues found that lostartan, a drug used widely in the clinic (e.g., to...

<font size="2" face="Arial"> </font> <font size="2" face="Arial">WINSTON-SALEM, N.C.</font>, Nov. 29, 2011 /PRNewswire-USNewswire/ -- It was the advice she got from her pediatrician and his wife five years ago, after her son Evan was diagnosed with Marfan syndrome, that still rings true to Susanna Hollingsworth. (Logo: <font size="2" face="Arial">http://photos.prnewswire.com/prnh/20111114/DC06171LOGO</font>) "They said 'Don't sit down at your...

Researchers at the Johns Hopkins University School of Medicine have found a protein normally involved in blood pressure regulation in a surprising place: tucked within the little "power plants" of cells, the mitochondria. The quantity of this protein appears to decrease with age, but treating older mice with the blood pressure medication losartan can increase protein numbers to youthful levels, decreasing both blood pressure and cellular energy usage. The researchers say these...

Paper accompanied by UK and US editorialsUsing a generic drug to treat hypertension and heart failure, instead of branded medicines from the same class, could save the UK National Health Service (NHS) at least £200 million in 2011 without any real reduction in clinical benefits.That is the key finding of a systematic review, statistical meta-analysis and cost-effectiveness analysis just published online by IJCP, the International Journal of Clinical Practice.Researchers from University...

MGH study finds losartan improves delivery of therapies in laboratory, animal modelsLow doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid...

(Ivanhoe Newswire) -- The difference between two angiotensin II receptor blockers (ARBs) -- candesartan and losartan -- is an important one. According to new research, one of them has a greater risk of death.ARBs are used to reduce cardiovascular mortality and to lower the need for hospitalization for patients with heart failures involving a reduced left ventricular ejection fraction (a measurement of left ventricular efficiency with each heart pump). ARBs have never been clinically compared,...

PITTSBURGH, Oct. 15 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approvals from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for the generic versions of Hyzaar® Tablets, 50 mg/12.5 mg and 100 mg/25 mg, and Cozaar® Tablets, 25 mg, 50 mg and 100 mg, both antihypertensives. Merck and Co. Inc.'s Hyzaar® is known generically as Losartan Potassium and...

MORRISTOWN, N.J., Oct. 12 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Losartan Potassium Tablets, USP, a generic version of Merck's Cozaar® in 25 mg, 50 mg and 100 mg strength. Losartan Potassium Tablets, USP were developed by Actavis R&D in Iceland. Losartan Potassium Tablets, USP had US sales of approximately $940 million for the 12 months ending...

COLUMBUS, Ohio, Oct. 6 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Losartan Potassium Tablets USP, 25mg, 50mg and 100mg as well as Losartan Potassium and Hydrochlorothiazide Tablets, 50mg/12.5mg and 100mg/25mg by the U.S. Food and Drug Administration. Both products are available for immediate shipment to wholesalers and pharmacies nationwide. Roxane Laboratories' Losartan Potassium Tablets USP are AB rated to...